Objective:To study the influence of mouse nerve growth factor (mNGF) combined with hyperbaric oxygen on serum cytokines and cognitive function in patients with delayed encephalopathy after carbon monoxide poisoning (D...Objective:To study the influence of mouse nerve growth factor (mNGF) combined with hyperbaric oxygen on serum cytokines and cognitive function in patients with delayed encephalopathy after carbon monoxide poisoning (DEACMP).Methods: 218 patients with DEACMP who were treated in our hospital between June 2012 and September 2016 were chosen as research subjects and retrospectively divided into the control group (n=100) who underwent hyperbaric oxygen treatment and the observation group (n=118) who underwent mouse nerve growth factor combined with hyperbaric oxygen treatment. Serum contents of nerve injury indexes and inflammatory mediators were compared between two groups of patients and cognitive function was assessed.Results:Before treatment, differences in serum levels of nerve injury indexes and inflammatory mediators, total MMSE score and each dimension score were not statistically significant between two groups of patients. After treatment, serum contents of nerve injury indexes creatine kinase-BB (CK-BB), neuron-specific enolase (NSE), S-100β protein (S-100β) and lactate (Lac) in observation group were lower than those in control group;serum contents of inflammatory mediators interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-18 (IL-18), hypersensitive C-reactive protein (hs-CRP) and tumor necrosis factor (TNF-α) were lower than those in control group;total MMSE score and each dimension score were higher than those of control group.Conclusion:mNGF combined with hyperbaric oxygen treatment of DEACMP is helpful to reduce the nerve injury and systemic inflammatory response, and improve the cognitive function.展开更多
Lead exposure is a known potential risk factor for neurodegenerative diseases such as Alzheimer’s disease （AD）. Exposure to lead during the critical phase of brain development has been linked with mental retardatio...Lead exposure is a known potential risk factor for neurodegenerative diseases such as Alzheimer’s disease （AD）. Exposure to lead during the critical phase of brain development has been linked with mental retardation and hypophrenia in later life.展开更多
BACKGROUND: Calcitonin gene-related peptide (CGRP) and nerve growth actor (NGF) cam improve spatial learning and memory abilities of rats with cerebral ischemia/reperfusion; however, the effect of combination of them ...BACKGROUND: Calcitonin gene-related peptide (CGRP) and nerve growth actor (NGF) cam improve spatial learning and memory abilities of rats with cerebral ischemia/reperfusion; however, the effect of combination of them on relieving learning and memory injury following cerebral ischemia/reperfusion should be further studied. OBJECTIVE: To study the effects of exogenous CGRP and NGF on learning and memory abilities of rats with focal cerebral ischemia/reperfusion. DESIGN: Randomized controlled animal study. SETTING: Department of Neurosurgery, the Second Hospital of Xiamen; Department of Neurosurgery, the Second Affiliated Hospital of China Medical University; Department of Neurobiology, Basic Medical College of China Medical University. MATERIALS: A total of 30 healthy male SD rats, aged 8 weeks, of clean grade, weighing 250-300 g, were provided by Experimental Animal Department of China Medical University. All rats were randomly divided into sham-operation group, ischemia/reperfusion group and treatment group with 10 in each group. The main reagents were detailed as the follows: 100 g/L chloral hydrate, 0.5 mL CGRP (2 mg/L, Sigma Company, USA), and NGF (1× 106 U/L, 0.5 mL, Siweite Company, Dalian). METHODS: The experiment was carried out in the Department of Neurobiology, Basic Medical College of China Medical University from February to July 2005. Rat models of middle cerebral artery occlusion were established by method of occlusion, 2 hours after that rats were anesthetized and the thread was slightly drawn out for 10 mm under direct staring to perform reperfusion. Rats in the ischemia/reperfusion group received intraperitoneal injection of 1 mL saline via the abdomen at two hours later, while rats in the treatment group at 2 hours later received intraperitoneal injection of 2 mg/L CGRP (0.5 mL) and 1×106 U/L NGF (0.5 mL) once a day for 10 successive days. First administration was accomplished within 15 minutes after ischemia/reperfusion. Rats in the sham-operation group were separated of the vessels without occlusion or administration. The neural function was evaluated with Zea Longa 5-grade scale. Animals with the score of one, two and three points received Morris water-maze test to measure searching time on platform (omitting platform-escaping latency). Meanwhile, leaning and memory abilities of animals were reflected through testing times of passing through platform per minute. MAIN OUTCOME MEASURES: Experimental results of omitting platform-escaping latency and spatial probe. RESULTS: Three and two rats in the ischemia/reperfusion group and treatment group respectively were not in accordance with the criteria in the process, and the rest were involved in the final analysis. ① Comparisons of platform-escaping latency during Morris water-maze test in all the three groups: Ten days after modeling, the platform-escaping latency in the ischemia/reperfusion group was obviously longer than that in sham-operation group (P < 0.01), and was significantly shorter than that in the treatment group (P < 0.01). ② Comparisons of times of passing through platform in all the three groups: Times of passing through platform were remarkably less in the ischemia/reperfusion group than those in the sham-operation group [(1.79±0.39), (4.30±0.73) times/minute, P < 0.01], and those were markedly more in the treatment group than the ischemia/reperfusion group [(3.16±1.03), (1.79±0.39) times/minute, P < 0.01]. CONCLUSION: CGRP and NGF are capable of ameliorating the abilities of spatial learning and memory in MCAO rats, which indicates that CGRP and NGF can protect ischemic neurons.展开更多
OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The...OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases. DATA RETRIEVAL： A computer-based retrieval was performed from six databases, including the Cochrane Library, PubMed, EMBASE, Sino Med, CNKI, and the VIP database, searching from the clinical establishment of nerve growth factor for treatment until December 31, 2013. The key words for the searches were ＂nerve growth factor, randomized controlled trials＂ in Chinese and in English. DATA SELECTION： Inclusion criteria： any study published in English or Chinese referring to randomized controlled trials of nerve growth factor; patients with neurological diseases such as peripheral nerve injury, central nerve injury, cranial neuropathy, and nervous system infections; patients older than 7 years; similar research methods and outcomes assessing symptoms; and measurement of nerve conduction velocities. The meta-analysis was conducted using Review Manager 5.2.3 software. MAIN OUTCOME MEASURES： The total effective rate, the incidence of adverse effects, and the nerve conduction velocity were recorded for each study. RESULTS： Sixty-four studies involving 6,297 patients with neurological diseases were included. The total effective rate in the group treated with nerve growth factor was significantly higher than that in the control group （P 〈 0.0001, RR： 1.35, 95%CI： 1.30-1.40）. The average nerve conduction velocity in the nerve growth factor group was significantly higher than that in the control group （P 〈 0.00001, MD. 4.59 m/s, 95%CI： 4.12-5.06）. The incidence of pain or sclero- ma at the injection site in the nerve growth factor group was also higher than that in the control group （P 〈 0.00001, RR： 6.30, 95%CI： 3.53-11.27）, but such adverse effects were mild. CONCLUSION： Nerve growth factor can significantly improve nerve function in patients with nervous system disease and is safe and effective.展开更多
Objective To explore the treatment effect of human growth factor(NGF)on vascular dementia.Method47cases with vascular dementia were randomly div ided into two groups(study and control).The study group(24cases)were tre...Objective To explore the treatment effect of human growth factor(NGF)on vascular dementia.Method47cases with vascular dementia were randomly div ided into two groups(study and control).The study group(24cases)were treated with NGF,the control group(23cases)were treated with ordinary medicines.Results The intelligence and cognitive abil ity in the study group were obviously higher than those in the control group(P <0.01).Conclusion Compared with other methods,NGF has a significant curative effect.展开更多
Objective:To study the effects of Urinary Kallidinogenase combined with mouse nerve growth factor (mNGF) on neurotrophic status, apoptosis and oxidative stress in patients with ischemic stroke.Methods: Patients with a...Objective:To study the effects of Urinary Kallidinogenase combined with mouse nerve growth factor (mNGF) on neurotrophic status, apoptosis and oxidative stress in patients with ischemic stroke.Methods: Patients with acute ischemic stroke who were treated in Jiangmen Central Hospital between March 2015 and October 2017 were selected and divided into two groups according to random number table method, the control group received conventional therapy, and the observation group received Urinary Kallidinogenase combined with mNGF therapy on the basis of routine therapy. The contents of neurotrophic cytokines, soluble apoptosis molecules and oxidative stress markers in serum were measured before treatment and 14d after treatment.Results:Serum BDNF, NTF, VEGF, HGF and IGF-1 levels of observation group after treatment were higher than those before treatment whereas serum BDNF, NTF, VEGF, HGF and IGF-1 levels of control group after treatment were not significantly different from those before treatment;serum sFas, sFasL, sTRAIL, 8-OHdG, Hcy and MDA levels of both groups after treatment were lower than those before treatment whereas Livin, Bcl-2, SOD and GSH-Px levels were higher than those before treatment;serum sFas, sFasL, sTRAIL, 8-OHdG, Hcy and MDA levels of observation group after treatment were lower than those of control group whereas BDNF, NTF, VEGF, HGF, IGF-1, Livin, Bcl-2, SOD and GSH-Px levels were higher than those of control group.Conclusion: Urinary Kallidinogenase combined with mNGF can improve the neurotrophic state and inhibit the apoptosis and oxidative stress response in patients with ischemic stroke.展开更多
目的探讨维生素B6联合鼠神经生长因子治疗难治性癫痫(refractory epilepsy,RE)患儿的疗效。方法选取RE患儿89例,根据住院号随机分为观察组(n=43)和对照组(n=46)。对照组在原抗癫痫药物治疗基础上联合应用左乙拉西坦片,观察组在对照组基...目的探讨维生素B6联合鼠神经生长因子治疗难治性癫痫(refractory epilepsy,RE)患儿的疗效。方法选取RE患儿89例,根据住院号随机分为观察组(n=43)和对照组(n=46)。对照组在原抗癫痫药物治疗基础上联合应用左乙拉西坦片,观察组在对照组基础上辅助应用维生素B6联合鼠神经生长因子治疗。比较两组患儿临床疗效,治疗前后外周血miR-99a-5p、miR-125b-5p、泛素羧基末端水解酶L1(ubiquitin C-terminal hydrolase-L1,UCH-L1)水平变化和对脑电活动的影响,评估患儿智力水平和生活质量改善情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组miR-99a-5p、miR-125b-5p、UCH-L1和θ波水平,均明显低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组语言智商、操作智商和总智商评分,儿童癫痫生活质量量表(quality of life in childhood epilepsy,QOLCE)总分,均明显高于对照组,差异有统计学意义(P<0.05)。结论维生素B6联合鼠神经生长因子治疗难治性癫痫效果较佳,可显著降低患儿外周血miR-99a-5p、miR-125b-5p、UCH-L1水平,控制脑电活动,从而改善患儿智力水平和生活质量。展开更多
文摘Objective:To study the influence of mouse nerve growth factor (mNGF) combined with hyperbaric oxygen on serum cytokines and cognitive function in patients with delayed encephalopathy after carbon monoxide poisoning (DEACMP).Methods: 218 patients with DEACMP who were treated in our hospital between June 2012 and September 2016 were chosen as research subjects and retrospectively divided into the control group (n=100) who underwent hyperbaric oxygen treatment and the observation group (n=118) who underwent mouse nerve growth factor combined with hyperbaric oxygen treatment. Serum contents of nerve injury indexes and inflammatory mediators were compared between two groups of patients and cognitive function was assessed.Results:Before treatment, differences in serum levels of nerve injury indexes and inflammatory mediators, total MMSE score and each dimension score were not statistically significant between two groups of patients. After treatment, serum contents of nerve injury indexes creatine kinase-BB (CK-BB), neuron-specific enolase (NSE), S-100β protein (S-100β) and lactate (Lac) in observation group were lower than those in control group;serum contents of inflammatory mediators interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-18 (IL-18), hypersensitive C-reactive protein (hs-CRP) and tumor necrosis factor (TNF-α) were lower than those in control group;total MMSE score and each dimension score were higher than those of control group.Conclusion:mNGF combined with hyperbaric oxygen treatment of DEACMP is helpful to reduce the nerve injury and systemic inflammatory response, and improve the cognitive function.
基金supported by the National Natural Science Foundation of China(NSFC),No.31201878,81172716,and U1204804Post Doctoral Foundation of China,No.2015M572109Post Doctoral Fund of Henan province,No.2014049
文摘Lead exposure is a known potential risk factor for neurodegenerative diseases such as Alzheimer’s disease （AD）. Exposure to lead during the critical phase of brain development has been linked with mental retardation and hypophrenia in later life.
文摘BACKGROUND: Calcitonin gene-related peptide (CGRP) and nerve growth actor (NGF) cam improve spatial learning and memory abilities of rats with cerebral ischemia/reperfusion; however, the effect of combination of them on relieving learning and memory injury following cerebral ischemia/reperfusion should be further studied. OBJECTIVE: To study the effects of exogenous CGRP and NGF on learning and memory abilities of rats with focal cerebral ischemia/reperfusion. DESIGN: Randomized controlled animal study. SETTING: Department of Neurosurgery, the Second Hospital of Xiamen; Department of Neurosurgery, the Second Affiliated Hospital of China Medical University; Department of Neurobiology, Basic Medical College of China Medical University. MATERIALS: A total of 30 healthy male SD rats, aged 8 weeks, of clean grade, weighing 250-300 g, were provided by Experimental Animal Department of China Medical University. All rats were randomly divided into sham-operation group, ischemia/reperfusion group and treatment group with 10 in each group. The main reagents were detailed as the follows: 100 g/L chloral hydrate, 0.5 mL CGRP (2 mg/L, Sigma Company, USA), and NGF (1× 106 U/L, 0.5 mL, Siweite Company, Dalian). METHODS: The experiment was carried out in the Department of Neurobiology, Basic Medical College of China Medical University from February to July 2005. Rat models of middle cerebral artery occlusion were established by method of occlusion, 2 hours after that rats were anesthetized and the thread was slightly drawn out for 10 mm under direct staring to perform reperfusion. Rats in the ischemia/reperfusion group received intraperitoneal injection of 1 mL saline via the abdomen at two hours later, while rats in the treatment group at 2 hours later received intraperitoneal injection of 2 mg/L CGRP (0.5 mL) and 1×106 U/L NGF (0.5 mL) once a day for 10 successive days. First administration was accomplished within 15 minutes after ischemia/reperfusion. Rats in the sham-operation group were separated of the vessels without occlusion or administration. The neural function was evaluated with Zea Longa 5-grade scale. Animals with the score of one, two and three points received Morris water-maze test to measure searching time on platform (omitting platform-escaping latency). Meanwhile, leaning and memory abilities of animals were reflected through testing times of passing through platform per minute. MAIN OUTCOME MEASURES: Experimental results of omitting platform-escaping latency and spatial probe. RESULTS: Three and two rats in the ischemia/reperfusion group and treatment group respectively were not in accordance with the criteria in the process, and the rest were involved in the final analysis. ① Comparisons of platform-escaping latency during Morris water-maze test in all the three groups: Ten days after modeling, the platform-escaping latency in the ischemia/reperfusion group was obviously longer than that in sham-operation group (P < 0.01), and was significantly shorter than that in the treatment group (P < 0.01). ② Comparisons of times of passing through platform in all the three groups: Times of passing through platform were remarkably less in the ischemia/reperfusion group than those in the sham-operation group [(1.79±0.39), (4.30±0.73) times/minute, P < 0.01], and those were markedly more in the treatment group than the ischemia/reperfusion group [(3.16±1.03), (1.79±0.39) times/minute, P < 0.01]. CONCLUSION: CGRP and NGF are capable of ameliorating the abilities of spatial learning and memory in MCAO rats, which indicates that CGRP and NGF can protect ischemic neurons.
基金supported by the National Science and Technology Major Projects for "Major New Drugs Innovation and Development",No.2012ZX09201-301-005
文摘OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases. DATA RETRIEVAL： A computer-based retrieval was performed from six databases, including the Cochrane Library, PubMed, EMBASE, Sino Med, CNKI, and the VIP database, searching from the clinical establishment of nerve growth factor for treatment until December 31, 2013. The key words for the searches were ＂nerve growth factor, randomized controlled trials＂ in Chinese and in English. DATA SELECTION： Inclusion criteria： any study published in English or Chinese referring to randomized controlled trials of nerve growth factor; patients with neurological diseases such as peripheral nerve injury, central nerve injury, cranial neuropathy, and nervous system infections; patients older than 7 years; similar research methods and outcomes assessing symptoms; and measurement of nerve conduction velocities. The meta-analysis was conducted using Review Manager 5.2.3 software. MAIN OUTCOME MEASURES： The total effective rate, the incidence of adverse effects, and the nerve conduction velocity were recorded for each study. RESULTS： Sixty-four studies involving 6,297 patients with neurological diseases were included. The total effective rate in the group treated with nerve growth factor was significantly higher than that in the control group （P 〈 0.0001, RR： 1.35, 95%CI： 1.30-1.40）. The average nerve conduction velocity in the nerve growth factor group was significantly higher than that in the control group （P 〈 0.00001, MD. 4.59 m/s, 95%CI： 4.12-5.06）. The incidence of pain or sclero- ma at the injection site in the nerve growth factor group was also higher than that in the control group （P 〈 0.00001, RR： 6.30, 95%CI： 3.53-11.27）, but such adverse effects were mild. CONCLUSION： Nerve growth factor can significantly improve nerve function in patients with nervous system disease and is safe and effective.
文摘Objective To explore the treatment effect of human growth factor(NGF)on vascular dementia.Method47cases with vascular dementia were randomly div ided into two groups(study and control).The study group(24cases)were treated with NGF,the control group(23cases)were treated with ordinary medicines.Results The intelligence and cognitive abil ity in the study group were obviously higher than those in the control group(P <0.01).Conclusion Compared with other methods,NGF has a significant curative effect.
文摘Objective:To study the effects of Urinary Kallidinogenase combined with mouse nerve growth factor (mNGF) on neurotrophic status, apoptosis and oxidative stress in patients with ischemic stroke.Methods: Patients with acute ischemic stroke who were treated in Jiangmen Central Hospital between March 2015 and October 2017 were selected and divided into two groups according to random number table method, the control group received conventional therapy, and the observation group received Urinary Kallidinogenase combined with mNGF therapy on the basis of routine therapy. The contents of neurotrophic cytokines, soluble apoptosis molecules and oxidative stress markers in serum were measured before treatment and 14d after treatment.Results:Serum BDNF, NTF, VEGF, HGF and IGF-1 levels of observation group after treatment were higher than those before treatment whereas serum BDNF, NTF, VEGF, HGF and IGF-1 levels of control group after treatment were not significantly different from those before treatment;serum sFas, sFasL, sTRAIL, 8-OHdG, Hcy and MDA levels of both groups after treatment were lower than those before treatment whereas Livin, Bcl-2, SOD and GSH-Px levels were higher than those before treatment;serum sFas, sFasL, sTRAIL, 8-OHdG, Hcy and MDA levels of observation group after treatment were lower than those of control group whereas BDNF, NTF, VEGF, HGF, IGF-1, Livin, Bcl-2, SOD and GSH-Px levels were higher than those of control group.Conclusion: Urinary Kallidinogenase combined with mNGF can improve the neurotrophic state and inhibit the apoptosis and oxidative stress response in patients with ischemic stroke.
文摘目的探讨维生素B6联合鼠神经生长因子治疗难治性癫痫(refractory epilepsy,RE)患儿的疗效。方法选取RE患儿89例,根据住院号随机分为观察组(n=43)和对照组(n=46)。对照组在原抗癫痫药物治疗基础上联合应用左乙拉西坦片,观察组在对照组基础上辅助应用维生素B6联合鼠神经生长因子治疗。比较两组患儿临床疗效,治疗前后外周血miR-99a-5p、miR-125b-5p、泛素羧基末端水解酶L1(ubiquitin C-terminal hydrolase-L1,UCH-L1)水平变化和对脑电活动的影响,评估患儿智力水平和生活质量改善情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组miR-99a-5p、miR-125b-5p、UCH-L1和θ波水平,均明显低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组语言智商、操作智商和总智商评分,儿童癫痫生活质量量表(quality of life in childhood epilepsy,QOLCE)总分,均明显高于对照组,差异有统计学意义(P<0.05)。结论维生素B6联合鼠神经生长因子治疗难治性癫痫效果较佳,可显著降低患儿外周血miR-99a-5p、miR-125b-5p、UCH-L1水平,控制脑电活动,从而改善患儿智力水平和生活质量。
